Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy

Autor: Christine Hoeffel, Damien Botsen, Christophe Portefaix, Mathilde Brasseur, Coralie Barbe, Eric Bertin, Marie-Amélie Ordan, Marine Perrier, Johanna Moreau, Yohann Renard, Barbara Tallière, Olivier Bouché, Camille Mazza
Přispěvatelé: Centre de Recherche en Sciences et Technologies de l'Information et de la Communication - EA 3804 (CRESTIC), Université de Reims Champagne-Ardenne (URCA), Faculté de Médecine de Reims, Centre Hospitalier Universitaire de Reims (CHU Reims)
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Cancer Research
medicine.medical_specialty
Colorectal cancer
Concordance
medicine.medical_treatment
Muscle mass
lcsh:RC254-282
Gastroenterology
Body Mass Index
Correlation
sarcopenia
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Muscle
Skeletal
Digestive cancer
ComputingMilieux_MISCELLANEOUS
Original Research
Aged
2. Zero hunger
digestive system neoplasms
Chemotherapy
Hand Strength
business.industry
Malnutrition
Clinical Cancer Research
dynapenia
Organ Size
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
3. Good health
030104 developmental biology
Oncology
muscle mass
030220 oncology & carcinogenesis
Sarcopenia
Muscle strength
muscle strength
Female
business
Tomography
X-Ray Computed
[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Zdroj: Cancer Medicine
Cancer Medicine, Wiley, 2019, 8 (8), pp.3677-3684. ⟨10.1002/cam4.2238⟩
Cancer Medicine, Vol 8, Iss 8, Pp 3677-3684 (2019)
ISSN: 2045-7634
DOI: 10.1002/cam4.2238⟩
Popis: International audience; BACKGROUND:FIGHTDIGO study has shown the feasibility of handgrip strength (HGS) measurements in 201 consecutive digestive cancer patients undergoing chemotherapy.OBJECTIVE:This study focuses on a secondary aim of FIGHTDIGO study: the relationship between muscle mass and HGS.DESIGN:Two consecutive bilateral measures of HGS were performed using a Jamar dynamometer before the start of each chemotherapy. The highest value was chosen for final evaluation. Dynapenia (loss of muscle strength) was defined as HGS < 30 kg (men) and < 20 kg (women). Muscle mass was measured at lumbar level (L3) on Computed Tomography (CT) scans performed less than 3 weeks before or after the measurement of HGS. Muscle mass loss was defined by skeletal muscle index (SMI) < 53 cm2 /m2 (in men with a body mass index (BMI)> 25 kg/m2 ), < 43 cm2 /m2 (in men with a BMI < 25 kg/m2 ), and < 41 cm2 /m2 (in women regardless of BMI). Sarcopenia was defined by the association of a dynapenia and a loss of muscle mass.RESULTS:A total of 150 patients were included in this analysis (mean age: 65.6 ± 10.9 years, 87 males (58%), colorectal cancer (47.3%), metastatic stage (76.7%)). A total of 348 CT scans were evaluated. For the 348 measurements, mean SMI and HGS were 41.8 ± 8.7 cm2 /m2 and 32.1 ± 11.0 kg, respectively. Muscle mass loss, dynapenia, or sarcopenia were reported at least once, in 120 (80%), 45 (30%), and 30 (20%) patients, respectively. SMI was significantly correlated with HGS (Pearson coefficient = 0.53, P < 0.0001). At concordance analysis, 188 dyad SMI/HGS (54%) were in agreement (Kappa = 0.14 [95% CI, 0.07-0.21]).CONCLUSION:Correlation between the measurements of HGS and SMI is strong but the concordance between dynapenia and muscle mass loss is poor. Further studies should be performed to confirm the diagnostic thresholds, and to study the chronology of dynapenia and loss of muscle mass.
Databáze: OpenAIRE
Externí odkaz: